Jennifer Makhoul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jennifer Makhoul has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Marie Chaftari
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
4 shared publications - Hiba Dagher
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
4 shared publications - Issam Raad
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
4 shared publications - Patrick Chaftari
Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
4 shared publications - Peter Lamie
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
4 shared publications - Ray Hachem
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
4 shared publications
Latest Publications
- 18 March 2026
- Published by Springer Nature in Neurocritical Care
- Vol. 45 (1) , 227-236
Vital Prognosis and Causes of Death in Adults with Encephalitis
Encephalitis in adults is associated with inpatient mortality in approximately 10% of patients, but the cause and timing of death are unknown. We conducted a retrospective study across two tertiary healthcare systems in Texas and Maryland between 2002 and 2023. Adults hospitalized with all-cause encephalitis were included. Our primary outcome was inpatient death. We investigated the association of various factors with mortality. The causes of death were categorized into three groups: category 1, where encephalitis was the direct cause of death; category 2, the underlying cause contributing to mortality but not directly responsible; or category 3, unrelated to the cause of death, acting independently. We subsequently examined the timing of death from initial presentation. A total of 629 adults with encephalitis were enrolled, 45 (7.15%) of whom died inpatient. In the cohort of 243 patients admitted to the intensive care unit (ICU), 41 deaths occurred, corresponding to a mortality rate of 16.87%. Logistic regression analysis identified body mass index (BMI), presence of comorbidities [Charlson Comorbidity Index (CCI] score], immunocompromise, memory deficits, elevated Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, altered mental status [Glasgow Coma Scale (GCS) score < 8], thrombocytopenia, hypoglycorrhachia, arrythmias, and ICU admission as significant predictors of mortality (p < 0.001 after Bonferroni correction). When restricting the analysis to patients admitted to the ICU, CCI score, psychiatric manifestations, memory deficits, and GCS retained statistical significance (p < 0.05). Encephalitis was the direct cause of death (category I) in 66% of cases with a median time to death of 12 days, the underlying cause (category 2) in 27% with a median of 14 days, and unrelated (category 3) in 7% within a median of 43 days. As for timing of death, 22% and 53% died in the first 7 and 14 days, respectively. All-cause encephalitis is associated with a low mortality rate of 7.15%, but higher among patients requiring ICU admission (16.87%). Among fatal cases, encephalitis was the direct or underlying cause of death in more than 90% of cases, with the majority of deaths occurring in the first 2 weeks.
- 18 March 2026
- Published by Springer Nature in Neurocritical Care
- Vol. 45 (1) , 227-236
Vital Prognosis and Causes of Death in Adults with Encephalitis
Encephalitis in adults is associated with inpatient mortality in approximately 10% of patients, but the cause and timing of death are unknown. We conducted a retrospective study across two tertiary healthcare systems in Texas and Maryland between 2002 and 2023. Adults hospitalized with all-cause encephalitis were included. Our primary outcome was inpatient death. We investigated the association of various factors with mortality. The causes of death were categorized into three groups: category 1, where encephalitis was the direct cause of death; category 2, the underlying cause contributing to mortality but not directly responsible; or category 3, unrelated to the cause of death, acting independently. We subsequently examined the timing of death from initial presentation. A total of 629 adults with encephalitis were enrolled, 45 (7.15%) of whom died inpatient. In the cohort of 243 patients admitted to the intensive care unit (ICU), 41 deaths occurred, corresponding to a mortality rate of 16.87%. Logistic regression analysis identified body mass index (BMI), presence of comorbidities [Charlson Comorbidity Index (CCI] score], immunocompromise, memory deficits, elevated Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, altered mental status [Glasgow Coma Scale (GCS) score < 8], thrombocytopenia, hypoglycorrhachia, arrythmias, and ICU admission as significant predictors of mortality (p < 0.001 after Bonferroni correction). When restricting the analysis to patients admitted to the ICU, CCI score, psychiatric manifestations, memory deficits, and GCS retained statistical significance (p < 0.05). Encephalitis was the direct cause of death (category I) in 66% of cases with a median time to death of 12 days, the underlying cause (category 2) in 27% with a median of 14 days, and unrelated (category 3) in 7% within a median of 43 days. As for timing of death, 22% and 53% died in the first 7 and 14 days, respectively. All-cause encephalitis is associated with a low mortality rate of 7.15%, but higher among patients requiring ICU admission (16.87%). Among fatal cases, encephalitis was the direct or underlying cause of death in more than 90% of cases, with the majority of deaths occurring in the first 2 weeks.
- 15 August 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (2) , 355-357
Ruxolitinib Meets a Forgotten Malady
- 15 August 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (2) , 355-357
Ruxolitinib Meets a Forgotten Malady
- Open Access
- 21 May 2025
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 33 (8) , 1816-1823
Whipple Disease Initial Presentation as Supraclavicular Lymphadenopathy in a Patient With Rheumatoid Arthritis: A Diagnostic Challenge
Whipple disease is a rare systemic disease caused by Tropheryma whipplei. It can present with a wide range of nonspecific symptoms that might overlap with underlying medical conditions, posing a diagnostic challenge. We present a 61-year-old man with a past medical history of rheumatoid arthritis and chronic inflammatory demyelinating polyneuropathy, who presented with persistent leukocytosis and supraclavicular lymphadenopathy. A positron emission tomography scan revealed hypermetabolic activity in the supraclavicular, abdominal, and pelvic lymph nodes along with a myocardial hypermetabolic lesion, concerning a lymphoproliferative disorder versus sarcoidosis. A supraclavicular lymph node excisional biopsy revealed complete architectural effacement by a diffuse foamy histiocytic infiltrate without granuloma formation or necrosis. The differential diagnosis included underlying infection, histiocytic neoplasm, lymphoproliferative disorder, storage disorder, and others. Immunostains show the histiocytic cells were positive for CD68 and CD163, while negative for S100, CD1a, kappa, lambda, and BRAF V600E. Grocott-Gömöri's methenamine silver and periodic acid–Schiff (PAS) stains demonstrated diffuse intracytoplasmic granular staining that was resistant to diastase treatment. Gram, acid fast bacilli, and Fite stains were negative. Electron microscopy revealed rod-shaped organisms with a trilaminar plasma membrane, morphologically consistent with T whipplei. Polymerase chain reaction was positive for T whipplei , confirming the diagnosis. Although rare, Whipple disease should be considered in immunocompromised patients presenting with nonspecific nongastrointestinal symptoms and lymphadenopathy clinically simulating lymphoma. Periodic acid–Schiff D-positive inclusions, along with confirmatory molecular results, are crucial for diagnosis. Whipple disease is a curable disease that can be lethal if unrecognized, emphasizing the importance of heightened awareness for early diagnosis and timely treatment.
- 21 May 2025
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 33 (8) , 1816-1823
Open AccessWhipple Disease Initial Presentation as Supraclavicular Lymphadenopathy in a Patient With Rheumatoid Arthritis: A Diagnostic Challenge
Whipple disease is a rare systemic disease caused by Tropheryma whipplei. It can present with a wide range of nonspecific symptoms that might overlap with underlying medical conditions, posing a diagnostic challenge. We present a 61-year-old man with a past medical history of rheumatoid arthritis and chronic inflammatory demyelinating polyneuropathy, who presented with persistent leukocytosis and supraclavicular lymphadenopathy. A positron emission tomography scan revealed hypermetabolic activity in the supraclavicular, abdominal, and pelvic lymph nodes along with a myocardial hypermetabolic lesion, concerning a lymphoproliferative disorder versus sarcoidosis. A supraclavicular lymph node excisional biopsy revealed complete architectural effacement by a diffuse foamy histiocytic infiltrate without granuloma formation or necrosis. The differential diagnosis included underlying infection, histiocytic neoplasm, lymphoproliferative disorder, storage disorder, and others. Immunostains show the histiocytic cells were positive for CD68 and CD163, while negative for S100, CD1a, kappa, lambda, and BRAF V600E. Grocott-Gömöri's methenamine silver and periodic acid–Schiff (PAS) stains demonstrated diffuse intracytoplasmic granular staining that was resistant to diastase treatment. Gram, acid fast bacilli, and Fite stains were negative. Electron microscopy revealed rod-shaped organisms with a trilaminar plasma membrane, morphologically consistent with T whipplei. Polymerase chain reaction was positive for T whipplei , confirming the diagnosis. Although rare, Whipple disease should be considered in immunocompromised patients presenting with nonspecific nongastrointestinal symptoms and lymphadenopathy clinically simulating lymphoma. Periodic acid–Schiff D-positive inclusions, along with confirmatory molecular results, are crucial for diagnosis. Whipple disease is a curable disease that can be lethal if unrecognized, emphasizing the importance of heightened awareness for early diagnosis and timely treatment.
- Open Access
- 3 May 2025
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (5)
Prognostic Value of Serum and Bronchoalveolar Lavage Fluid Galactomannan Levels in Invasive Aspergillosis: An 8-Year Experience at a Tertiary Cancer Center
Background: Invasive aspergillosis (IA) is a life-threatening fungal infection that primarily affects immunocompromised individuals and has high morbidity and mortality rates, necessitating timely diagnosis and treatment. This study aimed to evaluate the prognostic utility of serum and bronchoalveolar lavage (BAL) fluid galactomannan levels, as well as galactomannan kinetics, in patients with IA. Methods: We retrospectively reviewed the medical records of patients who were diagnosed with proven or probable IA from March 2016 to April 2024 at a tertiary cancer center. The collected data included patient characteristics, baseline and peak galactomannan levels in serum and BAL fluid, galactomannan trends, and clinical outcomes. Subgroup analyses were performed to assess the prognostic value of dual-source galactomannan positivity (positive serum and BAL fluid galactomannan levels). Results: Elevated baseline serum galactomannan levels independently predicted treatment non-response (p = 0.039) and 12-week all-cause mortality (p < 0.001). Peak serum and BAL fluid galactomannan levels were strongly associated with poor clinical outcomes (p < 0.01). Compared to single-source galactomannan positivity, dual-source galactomannan positivity was linked to reduced treatment response (22% vs. 43%, p = 0.01) and higher IA-attributable mortality (52% vs. 27%, p = 0.002). Patients with neutropenia had poorer outcomes compared to patients without neutropenia, but neutrophil recovery dramatically improved survival (25% vs. 69% mortality, p < 0.0001). Early galactomannan kinetics and malignancy type had limited prognostic value. Conclusions: Our findings highlight the potential role of galactomannan as a key biomarker for early prognostication for IA. The strong association between galactomannan levels and clinical outcomes suggests its utility in identifying high-risk patients who may benefit from more aggressive management. Further studies are needed to introduce a nuanced and context-specific use of galactomannan into clinical practice and assess its role as a prognostic biomarker.
- 3 May 2025
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (5)
Open AccessPrognostic Value of Serum and Bronchoalveolar Lavage Fluid Galactomannan Levels in Invasive Aspergillosis: An 8-Year Experience at a Tertiary Cancer Center
Background: Invasive aspergillosis (IA) is a life-threatening fungal infection that primarily affects immunocompromised individuals and has high morbidity and mortality rates, necessitating timely diagnosis and treatment. This study aimed to evaluate the prognostic utility of serum and bronchoalveolar lavage (BAL) fluid galactomannan levels, as well as galactomannan kinetics, in patients with IA. Methods: We retrospectively reviewed the medical records of patients who were diagnosed with proven or probable IA from March 2016 to April 2024 at a tertiary cancer center. The collected data included patient characteristics, baseline and peak galactomannan levels in serum and BAL fluid, galactomannan trends, and clinical outcomes. Subgroup analyses were performed to assess the prognostic value of dual-source galactomannan positivity (positive serum and BAL fluid galactomannan levels). Results: Elevated baseline serum galactomannan levels independently predicted treatment non-response (p = 0.039) and 12-week all-cause mortality (p < 0.001). Peak serum and BAL fluid galactomannan levels were strongly associated with poor clinical outcomes (p < 0.01). Compared to single-source galactomannan positivity, dual-source galactomannan positivity was linked to reduced treatment response (22% vs. 43%, p = 0.01) and higher IA-attributable mortality (52% vs. 27%, p = 0.002). Patients with neutropenia had poorer outcomes compared to patients without neutropenia, but neutrophil recovery dramatically improved survival (25% vs. 69% mortality, p < 0.0001). Early galactomannan kinetics and malignancy type had limited prognostic value. Conclusions: Our findings highlight the potential role of galactomannan as a key biomarker for early prognostication for IA. The strong association between galactomannan levels and clinical outcomes suggests its utility in identifying high-risk patients who may benefit from more aggressive management. Further studies are needed to introduce a nuanced and context-specific use of galactomannan into clinical practice and assess its role as a prognostic biomarker.
- Open Access
- 7 March 2025
- Published by MDPI AG in Preprints.org
Prognostic Value of Serum and Bronchoalveolar Lavage Fluid Galactomannan Levels in Invasive Aspergillosis: An 8-Year Experience at a Tertiary Cancer Center
Background: Invasive aspergillosis (IA) is a life-threatening fungal infection that primarily affects immunocompromised individuals and has high morbidity and mortality rates, necessitating timely diagnosis and treatment. This study aimed to evaluate the prognostic utility of serum and bronchoalveolar lavage (BAL) fluid galactomannan levels, as well as galactomannan kinetics, in patients with IA. Methods: We retrospectively reviewed the medical records of patients who were diagnosed with proven or probable IA from March 2016 to April 2024 at a tertiary cancer center. The collected data included patient characteristics, baseline and peak galactomannan levels from serum and BAL fluid, galactomannan trends, and clinical outcomes. Subgroup analyses were performed to assess the prognostic value of dual-source galactomannan positivity (positive serum and BAL galactomannan levels). Results: Elevated baseline serum galactomannan levels independently predicted treatment non-response (P = 0.039) and 12-week all-cause mortality (P < 0.001). Peak serum and BAL galactomannan levels were strongly associated with poor clinical outcomes (P < 0.01). Compared to single-source galactomannan positivity, dual-source galactomannan positivity was linked to reduced treatment response (22% vs. 42%, P = 0.009) and higher IA-attributable mortality (52% vs. 28%, P = 0.002). Patients with neutropenia had poorer outcomes compared to patients without neutropenia, but neutrophil recovery dramatically improved survival (25% vs. 69% mortality, P < 0.0001). Early galactomannan kinetics and malignancy type had limited prognostic value. Conclusion: Our findings highlight the potential role of galactomannan as a key biomarker for early prognostication for IA. The strong association between galactomannan levels and clinical outcomes suggests its utility in identifying high-risk patients who may benefit from more aggressive management. Further studies are needed to introduce a nuanced and context-specific use of galactomannan into clinical practice and assess its role as a prognostic biomarker.
- 7 March 2025
- Published by MDPI AG in Preprints.org
Open AccessPrognostic Value of Serum and Bronchoalveolar Lavage Fluid Galactomannan Levels in Invasive Aspergillosis: An 8-Year Experience at a Tertiary Cancer Center
Background: Invasive aspergillosis (IA) is a life-threatening fungal infection that primarily affects immunocompromised individuals and has high morbidity and mortality rates, necessitating timely diagnosis and treatment. This study aimed to evaluate the prognostic utility of serum and bronchoalveolar lavage (BAL) fluid galactomannan levels, as well as galactomannan kinetics, in patients with IA. Methods: We retrospectively reviewed the medical records of patients who were diagnosed with proven or probable IA from March 2016 to April 2024 at a tertiary cancer center. The collected data included patient characteristics, baseline and peak galactomannan levels from serum and BAL fluid, galactomannan trends, and clinical outcomes. Subgroup analyses were performed to assess the prognostic value of dual-source galactomannan positivity (positive serum and BAL galactomannan levels). Results: Elevated baseline serum galactomannan levels independently predicted treatment non-response (P = 0.039) and 12-week all-cause mortality (P < 0.001). Peak serum and BAL galactomannan levels were strongly associated with poor clinical outcomes (P < 0.01). Compared to single-source galactomannan positivity, dual-source galactomannan positivity was linked to reduced treatment response (22% vs. 42%, P = 0.009) and higher IA-attributable mortality (52% vs. 28%, P = 0.002). Patients with neutropenia had poorer outcomes compared to patients without neutropenia, but neutrophil recovery dramatically improved survival (25% vs. 69% mortality, P < 0.0001). Early galactomannan kinetics and malignancy type had limited prognostic value. Conclusion: Our findings highlight the potential role of galactomannan as a key biomarker for early prognostication for IA. The strong association between galactomannan levels and clinical outcomes suggests its utility in identifying high-risk patients who may benefit from more aggressive management. Further studies are needed to introduce a nuanced and context-specific use of galactomannan into clinical practice and assess its role as a prognostic biomarker.
- Open Access
- 19 February 2025
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (2) , 160
Outcome Analysis of Breakthrough Invasive Aspergillosis on Anti-Mold Azole Prophylaxis and Treatment: 30-Year Experience in Hematologic Malignancy Patients
Background: Anti-mold azoles have improved the outcomes of invasive aspergillosis (IA) when used therapeutically, but they are extensively used as prophylaxis. There are limited data regarding the outcomes of patients with hematologic malignancy who develop breakthrough IA on anti-mold azoles. We aimed to determine whether breakthrough IA on azole prophylaxis shows worse outcomes compared to no prophylaxis. Methods: We compared outcomes including therapy response and mortality between antifungal regimens in hematologic malignancy patients with IA between July 1993 and July 2023. Results: Compared to an amphotericin B-containing regimen (AMB), an anti-mold azole as the primary therapy was independently associated with successful response at the end of therapy (OR = 4.38, p < 0.0001), protective against 42-day IA-associated mortality (OR = 0.51, p = 0.024) or all cause mortality (OR = 0.35, p < 0.0001), and protective against 84-day mortality, both IA-associated (OR = 0.50, p = 0.01) and all-cause mortality (OR = 0.27, p < 0.0001). Azole prophylaxis was independently associated with higher IA-associated mortality at 42 days (OR = 1.91, p = 0.012) and 84 days (OR = 2.03, p = 0.004), compared to fluconazole or no prophylaxis. Conclusions: Patients with breakthrough IA on anti-mold azole prophylaxis show a worse prognosis than those on other or no prophylaxis, possibly related to the emergence of azole resistance due to their widespread use as prophylaxis agents. On the other hand, anti-mold azole primary therapy is superior to AMB therapy in the treatment of IA.
- 19 February 2025
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (2) , 160
Open AccessOutcome Analysis of Breakthrough Invasive Aspergillosis on Anti-Mold Azole Prophylaxis and Treatment: 30-Year Experience in Hematologic Malignancy Patients
Background: Anti-mold azoles have improved the outcomes of invasive aspergillosis (IA) when used therapeutically, but they are extensively used as prophylaxis. There are limited data regarding the outcomes of patients with hematologic malignancy who develop breakthrough IA on anti-mold azoles. We aimed to determine whether breakthrough IA on azole prophylaxis shows worse outcomes compared to no prophylaxis. Methods: We compared outcomes including therapy response and mortality between antifungal regimens in hematologic malignancy patients with IA between July 1993 and July 2023. Results: Compared to an amphotericin B-containing regimen (AMB), an anti-mold azole as the primary therapy was independently associated with successful response at the end of therapy (OR = 4.38, p < 0.0001), protective against 42-day IA-associated mortality (OR = 0.51, p = 0.024) or all cause mortality (OR = 0.35, p < 0.0001), and protective against 84-day mortality, both IA-associated (OR = 0.50, p = 0.01) and all-cause mortality (OR = 0.27, p < 0.0001). Azole prophylaxis was independently associated with higher IA-associated mortality at 42 days (OR = 1.91, p = 0.012) and 84 days (OR = 2.03, p = 0.004), compared to fluconazole or no prophylaxis. Conclusions: Patients with breakthrough IA on anti-mold azole prophylaxis show a worse prognosis than those on other or no prophylaxis, possibly related to the emergence of azole resistance due to their widespread use as prophylaxis agents. On the other hand, anti-mold azole primary therapy is superior to AMB therapy in the treatment of IA.
- Open Access
- 5 February 2025
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (2) , 119
Decreased Frequency and Improved Outcomes in Invasive Aspergillosis Caused by Aspergillus terreus After the Introduction of Anti-Mold Azole Agents: A 30-Year Study at a Tertiary Cancer Center
Invasive aspergillosis (IA) is a significant cause of morbidity and mortality in patients with hematological malignancy (HM) and hematopoietic stem cell transplant (HSCT) recipients. Aspergillus terreus is associated with worse outcomes than non-terreus Aspergillus species. Since the introduction of anti-mold azoles in 2002, there have been limited data on the etiology of IA. We retrospectively compared characteristics, antifungal treatments, and outcomes between patients with HM or HSCT infected with A. terreus and those with non-terreus Aspergillus between July 1993 and July 2023. We also examined trends over time in rates of A. terreus and outcomes of this infection. A total of 699 patients with culture-documented IA were analyzed, 537 with non-terreus species and 162 with A. terreus. Types of underlying malignancy, neutropenia, graft-versus-host disease, and anti-mold prophylaxis were similar between the groups. ICU stays and mechanical ventilation were more common among patients with A. terreus (p = 0.002 and 0.003, respectively). The rate of A. terreus decreased significantly from 35.9% during 1993–2003 to 11.2% during 2004–2013 and 16.7% during 2014–2023 (p < 0.0001 each). IA caused by A. terreus showed significant improvements in response to therapy and in overall and IA-associated mortality in the last two decades compared to the first (p < 0.0001). In conclusion, the increased use of anti-mold azoles after 2003 improved outcomes for HM patients with IA caused by A. terreus.
- 5 February 2025
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (2) , 119
Open AccessDecreased Frequency and Improved Outcomes in Invasive Aspergillosis Caused by Aspergillus terreus After the Introduction of Anti-Mold Azole Agents: A 30-Year Study at a Tertiary Cancer Center
Invasive aspergillosis (IA) is a significant cause of morbidity and mortality in patients with hematological malignancy (HM) and hematopoietic stem cell transplant (HSCT) recipients. Aspergillus terreus is associated with worse outcomes than non-terreus Aspergillus species. Since the introduction of anti-mold azoles in 2002, there have been limited data on the etiology of IA. We retrospectively compared characteristics, antifungal treatments, and outcomes between patients with HM or HSCT infected with A. terreus and those with non-terreus Aspergillus between July 1993 and July 2023. We also examined trends over time in rates of A. terreus and outcomes of this infection. A total of 699 patients with culture-documented IA were analyzed, 537 with non-terreus species and 162 with A. terreus. Types of underlying malignancy, neutropenia, graft-versus-host disease, and anti-mold prophylaxis were similar between the groups. ICU stays and mechanical ventilation were more common among patients with A. terreus (p = 0.002 and 0.003, respectively). The rate of A. terreus decreased significantly from 35.9% during 1993–2003 to 11.2% during 2004–2013 and 16.7% during 2014–2023 (p < 0.0001 each). IA caused by A. terreus showed significant improvements in response to therapy and in overall and IA-associated mortality in the last two decades compared to the first (p < 0.0001). In conclusion, the increased use of anti-mold azoles after 2003 improved outcomes for HM patients with IA caused by A. terreus.
- 28 August 2021
- Published by SAGE Publications in Journal of Infection Prevention
- Vol. 22 (6) , 289-292
Lack of regulation over antibiotic prescription and dispensation: A prospective cohort in a community setting
Background: The emergence of bacterial resistance caused health authorities to attempt to implement strict regulations for rational antibiotic prescription. However, supervision is often neglected in low- and middle-income countries, leading to inappropriate administration of antibiotics. The objective of our study is to highlight the lack of monitoring in the community setting of a middle-income country. Material and methods: We asked 68 patients presenting to an infectious diseases consultation office to report the antibiotic courses they had taken in the three months preceding their visit. We assessed for treatment indication, molecule choice, dosing and duration, as well as microbial cultures, demographics and specialty of the prescriber. Results: Among the 68 patients included in our study, we counted a total of 95 outpatient antibiotic courses, mostly composed of quinolones (36%), followed by amoxicillin-clavulanate (21%). The prescriber was most commonly a primary care physician, but we reported several cases of auto-medication and dispensation of antibiotics by pharmacists. Only 30% of cases had true indications for antibiotics. Conclusion: In sum, our results indicate an evident lack of regulation over the administration of antibiotics. This easy accessibility needs to be promptly addressed as we run the risk of inevitable bacterial resistance.
- 28 August 2021
- Published by SAGE Publications in Journal of Infection Prevention
- Vol. 22 (6) , 289-292
Lack of regulation over antibiotic prescription and dispensation: A prospective cohort in a community setting
Background: The emergence of bacterial resistance caused health authorities to attempt to implement strict regulations for rational antibiotic prescription. However, supervision is often neglected in low- and middle-income countries, leading to inappropriate administration of antibiotics. The objective of our study is to highlight the lack of monitoring in the community setting of a middle-income country. Material and methods: We asked 68 patients presenting to an infectious diseases consultation office to report the antibiotic courses they had taken in the three months preceding their visit. We assessed for treatment indication, molecule choice, dosing and duration, as well as microbial cultures, demographics and specialty of the prescriber. Results: Among the 68 patients included in our study, we counted a total of 95 outpatient antibiotic courses, mostly composed of quinolones (36%), followed by amoxicillin-clavulanate (21%). The prescriber was most commonly a primary care physician, but we reported several cases of auto-medication and dispensation of antibiotics by pharmacists. Only 30% of cases had true indications for antibiotics. Conclusion: In sum, our results indicate an evident lack of regulation over the administration of antibiotics. This easy accessibility needs to be promptly addressed as we run the risk of inevitable bacterial resistance.
- Open Access
- 1 September 2020
- Published by Elsevier in New Microbes and New Infections
- Vol. 37, 100750
Are two consecutive negative RT-PCR results enough to rule out COVID-19?
- 1 September 2020
- Published by Elsevier in New Microbes and New Infections
- Vol. 37, 100750
Open AccessAre two consecutive negative RT-PCR results enough to rule out COVID-19?